Human Organoids Market size is expected to reach USD 3 Billion by the end of 2035, witnessing around 18% CAGR during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of human organoids was USD 2 Billion. The growth of the market can be attributed to the rising incidence of infectious diseases, the growing need for organ transplants, along with the growing investment in the advancement of medical technologies, are expected to fuel the progress of the market. According to the U.S. Department Health Resources & Services Administration (HRSA) over 39,000 transplants were performed in 2020 in the US, while 17 people die each day waiting for an organ transplant.
In addition to these, factors that are believed to fuel the market growth of human organoids include the rising development of efficient tools and mechanisms for early diagnosis & treatment of infectious diseases that can facilitate more effective and rapid responses to medical conditions. Human organoids allow the creation of cellular models of clinical problems, such as infectious & genetic diseases, tumor modeling & bio-banking, gene function, and cell development, to further study them in the laboratory and develop accurate treatment methods. This is anticipated to be the major growth driver for the market. The growth of the market can also be attributed to the extensive medical research associated with drug discovery in western countries and the rising demand for advanced drugs. Human organoids may also be deployed for the customization of therapy or personalized medicine, which is also expected to contribute to the growth of the market.
Growth Drivers
Rising Prevalence of Infectious Disease – Human organoids offer a chance to enhance human health in connection to infectious illnesses. Annual influenza A and B epidemics in the US from 2010 to 2020 caused 9–45 million infections, 140,000–810,000 hospitalizations, and 12,000–61,000 fatalities per year. Moreover, SARS-CoV-2 caused more than 22.3 million reported infections and more than 373,000 fatalities from COVID-19 in the US between January 21, 2020, and January 11, 2021.
Higher Procedure of Organ Transplantation – Human organoids are helpful in drug testing of transplantation therapy. Compared to the number of available organs, a lot more people need transplants. While 95% of American adults support organ donation, just 54% are actually registered donors.
Higher Use of Human Genes for Experiment – Human organoids can study human genes for treating major disease, such as cancer, genetic disorders, and others. More than 300 million samples of human tissue are thought to exist in various collections around the globe.
Increasing Clinical Trials for Regenerative Medicines – Preclinical drug testing of regenerative medicines uses human organoids in biomedical research. There are now more than 1,500 clinical trials including regenerative medicine. Clinical trials for regenerative medicine grew overall between 2005 and 2018, with the highest percentage that is around 10% of studies occurring in 2020.
Rising Investment in Organoids Development - Investment in organoids study is likely to drive market growth. Prior to Phase 2a studies, LyGenesis, Inc. has raised USD 4 million, which works as a stepping stone to a larger investment round in 2020.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~18% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 3 Billion |
|
Regional Scope |
|
Product (Pancreas, Kidney, Lungs, Heart, Liver Models)
The global human organoids market is segmented and analyzed for demand and supply by product into pancreas, kidney, lungs, heart, liver models, and others. Out of the six types of irritable bowel syndrome, the kidney segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing number of kidney transplants performed globally as compared to other procedures. As per the statistics by the National Kidney Foundation, there were 121,678 people waiting for lifesaving organ transplants in the U.S. in 2020. Out of these, 100,791 individuals were waiting for kidney transplants. Moreover, there has been a significant growth in kidney-related diseases, which is also projected to contribute to the growth of the segment during the forecast period.
End-user (Biotech & Pharma, Academic & Research Institutes, Hospitals & Diagnostic Centers)
The global human organoids market is also segmented and analyzed for demand and supply by end-user into biotech & pharma industry, academic & research institutes, hospitals & diagnostic centers, and others. Amongst these four segments, the biotech & pharma industry segment is expected to garner a significant share. The growth of the segment is expected on the back of increasing focus of biotech & pharma industry on research and development related to new drug discovery for the treatment of various rare diseases, combined with technological developments in the field of 3D bioprinting.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By End User |
|
APAC Market Statistics
The Asia Pacific human organoids market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the rising need for organ transplantation and donation. It is projected that around 180,000 people experience renal failure every year, out of which only 6000 kidney transplants are carried out. Moreover, around 10-15% of the 200,000 individuals dies in India each year from liver cancer or failure. However, they could be spared with a prompt liver transplant. As a result, India needs between 25 and 30 thousand liver transplants each year. Furthermore, rising cases of infectious disease in the region is also expected to boost the market growth in Asia Pacific. More than 1 million cases of contagious diarrhea were reported in China in 2021.
North American Market Forecast
The North American human organoids market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The market growth in the region is attributed to the high technological advancement in the field of transplantation, accompanied by the presence of well-established distribution channels for the supply of human organoid products in the region. Along with this, North America also leads in terms of government healthcare expenditure, which is also expected to contribute to the market growth in the region. According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America.
Thermo Fisher Scientific declared to acquire PPD, Inc. for USD 47.50 per share. This acquisition establishes Thermo Fisher as a global leader in the clinical research service industry.
CELLINK announced its acquisition of MatTek Corporation to expand its portfolio to advance in-vitro technology.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?